Cover Image
Market Research Report

Cytomegalovirus (HHV-5) Infections Global Clinical Trials Review, H2, 2017

Published by GlobalData Product code 246382
Published Content info 217 Pages
Immediate Delivery Available
Price
Back to Top
Cytomegalovirus (HHV-5) Infections Global Clinical Trials Review, H2, 2017
Published: July 19, 2017 Content info: 217 Pages
Description

GlobalData's clinical trial report, "Cytomegalovirus (HHV-5) Infections Global Clinical Trials Review, H2, 2017" provides an overview of Cytomegalovirus (HHV-5) Infections clinical trials scenario. This report provides top line data relating to the clinical trials on Cytomegalovirus (HHV-5) Infections. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents
Product Code: GDHC4360CTIDB

Table of Contents

Table of Contents

Table of Contents 2

  • List of Tables 4
  • List of Figures 5
  • Report Guidance 6
  • GlobalData Clinical Trials Report Coverage 7
  • Clinical Trials by Region 8
  • Clinical Trials and Average Enrollment by Country 9
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific 12
  • Top Five Countries Contributing to Clinical Trials in Europe 13
  • Top Countries Contributing to Clinical Trials in North America 14
  • Top Countries Contributing to Clinical Trials in Middle East and Africa 15
  • Top Countries Contributing to Clinical Trials in Central and South America 16
  • Clinical Trials by G7 Countries: Proportion of Cytomegalovirus (HHV-5) Infections to Infectious Disease Clinical Trials 17
  • Clinical Trials by Phase in G7 Countries 19
  • Clinical Trials in G7 Countries by Trial Status 20
  • Clinical Trials by E7 Countries: Proportion of Cytomegalovirus (HHV-5) Infections to Infectious Disease Clinical Trials 22
  • Clinical Trials by Phase in E7 Countries 24
  • Clinical Trials in E7 Countries by Trial Status 25
  • Clinical Trials by Phase 26
  • In Progress Trials by Phase 27
  • Clinical Trials by Trial Status 28
  • Clinical Trials by End Point Status 30
  • Subjects Recruited Over a Period of Time 31
  • Clinical Trials by Sponsor Type 32
  • Prominent Sponsors 33
  • Top Companies Participating in Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials 35
  • Prominent Drugs 37
  • Latest Clinical Trials News on Cytomegalovirus (HHV-5) Infections 38
  • Jul 11, 2017: ViraCyte Completes Phase 1 Clinical Trial of Viralym-C 38
  • May 30, 2017: Merck To Present Data on Letermovir at ASM Microbe 2017 38
  • May 04, 2017: Hookipa Biotech Presents Positive Data from Phase 1 First-In-Human Trial of Vaccine Against Cytomegalovirus 38
  • May 02, 2017: VBI Vaccines Provides Update on its Congenital CMV Phase I Clinical Study 39
  • Apr 19, 2017: Merck Underscores Continued Commitment to Fighting Infectious Diseases With More than 25 Data Presentations at ECCMID 2017 39
  • Clinical Trial Profile Snapshots 40

Appendix 215

  • Abbreviations 215
  • Definitions 215
  • Research Methodology 216
  • Secondary Research 216
  • About GlobalData 217
  • Contact Us 217
  • Source 217

List of Tables

List of Tables

  • Cytomegalovirus (HHV-5) Infections Therapeutics, Global, Clinical Trials by Region, 2017* 8
  • Cytomegalovirus (HHV-5) Infections Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 10
  • Cytomegalovirus (HHV-5) Infections Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 11
  • Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017* 12
  • Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 13
  • Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials, North America, Top Countries, 2017* 14
  • Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2017* 15
  • Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials, Central and South America, Top Countries, 2017* 16
  • Proportion of Cytomegalovirus (HHV-5) Infections to Infectious Disease Clinical Trials, G7 Countries (%), 2017* 18
  • Cytomegalovirus (HHV-5) Infections Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 19
  • Cytomegalovirus (HHV-5) Infections Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 21
  • Proportion of Cytomegalovirus (HHV-5) Infections to Infectious Disease Clinical Trials, E7 Countries (%), 2017* 23
  • Cytomegalovirus (HHV-5) Infections Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 24
  • Cytomegalovirus (HHV-5) Infections Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 25
  • Cytomegalovirus (HHV-5) Infections Therapeutics, Global, Clinical Trials by Phase, 2017* 26
  • Cytomegalovirus (HHV-5) Infections Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 27
  • Cytomegalovirus (HHV-5) Infections Therapeutics, Global, Clinical Trials by Trial Status, 2017* 29
  • Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials, Global, by End Point Status, 2017* 30
  • Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 31
  • Cytomegalovirus (HHV-5) Infections Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 32
  • Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 34
  • Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 36
  • Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 37

List of Figures

List of Figures

  • Cytomegalovirus (HHV-5) Infections Therapeutics, Global, Clinical Trials by Region (%), 2017* 8
  • Cytomegalovirus (HHV-5) Infections Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 9
  • Cytomegalovirus (HHV-5) Infections Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 11
  • Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2017* 12
  • Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017* 13
  • Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials, North America, Top Countries (%), 2017* 14
  • Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2017* 15
  • Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2017* 16
  • Proportion of Cytomegalovirus (HHV-5) Infections to Infectious Disease Clinical Trials, G7 Countries (%), 2017* 17
  • Cytomegalovirus (HHV-5) Infections Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 19
  • Cytomegalovirus (HHV-5) Infections Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 20
  • Proportion of Cytomegalovirus (HHV-5) Infections to Infectious Disease Clinical Trials, E7 Countries (%), 2017* 22
  • Cytomegalovirus (HHV-5) Infections Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 24
  • Cytomegalovirus (HHV-5) Infections Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 25
  • Cytomegalovirus (HHV-5) Infections Therapeutics, Global, Clinical Trials by Phase (%), 2017* 26
  • Cytomegalovirus (HHV-5) Infections Therapeutics, Global, Clinical Trials In Progress by Phase, 2017* 27
  • Cytomegalovirus (HHV-5) Infections Therapeutics, Global, Clinical Trials by Trial Status, 2017* 28
  • Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials, Global, by End Point Status, 2017* 30
  • Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 31
  • Cytomegalovirus (HHV-5) Infections Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017* 32
  • Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 33
  • Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 35
  • Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 37
  • GlobalData Methodology 216
Back to Top